Targeting the PD-1 pathway: a new hope for gastrointestinal cancers


BİLGİN B., ŞENDUR M. A. N. , AKINCI M. B. , Dede D. S. , YALÇIN B.

CURRENT MEDICAL RESEARCH AND OPINION, cilt.33, ss.749-759, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 33 Konu: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/03007995.2017.1279132
  • Dergi Adı: CURRENT MEDICAL RESEARCH AND OPINION
  • Sayfa Sayıları: ss.749-759

Özet

Background: VEGF, HER2 and EGFR targeted agents are currently used in gastric, esophageal and colorectal cancers. However, treatment outcomes are still poor in most gastrointestinal (GI) cancers. Immune checkpoints are one of the most promising immunotherapy approaches. In this review article, we aim to discuss the efficacy and safety of anti-PD-1/PD-L1 therapies in GI cancers, including gastric, esophageal and colorectal cancer in published or reported recent studies.